Tempus Announces the GEMINI Non-Small Cell Lung Cancer Study
Study aims to create the most robust, multi-omic dataset for patients with NSCLC
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
13 Jul 23
Study aims to create the most robust, multi-omic dataset for patients with NSCLC
12 Jul 23
Columvi is a T-cell-engaging bispecific antibody engineered to have one region that binds to CD3, a protein on…
12 Jul 23
The US-based biopharma company is now focusing its multi-pronged malaria programme to address the chronic malaria crisis in…
12 Jul 23
In the study, the positive topline results showed significantly more patients treated with ruxolitinib cream 0.75% and 1.5%…
12 Jul 23
The decision was made by the firm after consultation with the data monitoring committee regarding results data from…
12 Jul 23
The financing will support the progression of Septerna’s lead programme, which targets the parathyroid hormone 1 receptor (PTH1R),…
12 Jul 23
Asahi Kasei announced that it is moving the global headquarters for its Healthcare Business to the United States.…
12 Jul 23
The Acquisition was completed on July 11, 2023, US Eastern Time, as follows, and Iveric Bio has become…
12 Jul 23
Advances World-Class Clinical Research Capabilities with Leading Regulatory-Grade Registries Platform. Expected to Be Immediately Accretive to Adjusted Earnings…
12 Jul 23
Labafenogene marselecobac (previously known as SYNB1934) is an orally administered, non-systemically absorbed, potential treatment for phenylketonuria (PKU), a…